THE SIGNIFICANCE OF C‑REACTIVE PROTEIN IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.17650/1818-8338-2012-1-10-14
Abstract
It is believed that the concentration of C‑reactive protein (CRP) significantly increases in acute forms of systemic lupus erythematosus (SLE). A moderate increase of CRP levels in patients with stable disease progression reflects the low‑grade chronic inflammation in the vascular wall and the development of subclinical atherosclerosis. The article presents data showing that increased CRP levels in SLE patients is not statistically related with disease activity and cardiovascular risk as well as the level of interleykin‑6. Patients with lupus nephritis have lower CRP concentration compared to patients without renal disease and CRP concentration depends on proteinuria and hypoalbuminemia.
About the Authors
S. M. Noskov
Yaroslavl state medical academy, Ministry of Health and Social Development of Russia
Russian Federation
Chair of hospital therapy
Russian Federation
Chair of hospital therapy
O. A. Vasilevskaja
Yaroslavl state medical academy, Ministry of Health and Social Development of Russia
Russian Federation
Chair of hospital therapy
Russian Federation
Chair of hospital therapy
T. S. Noskova
Yaroslavl state medical academy, Ministry of Health and Social Development of Russia
Russian Federation
Chair of hospital therapy
Russian Federation
Chair of hospital therapy
N. A. Arzimanova
Yaroslavl state medical academy, Ministry of Health and Social Development of Russia
Russian Federation
Chair of hospital therapy
Russian Federation
Chair of hospital therapy
References
1. Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР‑Медиа; 2011.
2. Karadag O., Calguneri M., Atalar E., et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol 2007;
3. (5):695−9.
4. Jialal K., Devaraj S., Venugopal S.K. C‑reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004;44:6−11.
5. Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы ревматологии. Научно-практическая ревматология 2004;(4):4−9.
6. Breda L., Nozzi M., De Sanctis S., Chiarelli F. Laboratory tests in the diagnosis and follow‑up of pediatric rheumatic diseases: an update. Semin Arthritis Rheum 2010;40(1):53−72.
7. Sjöwall C., Wetterö J. Pathogenic implications for autoantibodies against C‑reactive protein and
8. other acute phase proteins. Clin Chim Acta 2007; 378(1−2):13−23.
9. Marnell L., Mold C., Du Clos T.W. C‑reactive protein: ligands, receptors and role in inflammation.
10. Clin Immunol 2005;117(2):104−11.
11. Rhodes B., Fürnrohr B.G., Vyse T.J. C‑reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011;7(5):282−9.
12. Shih P.B., Manzi S., Shaw P., et al. Genetic variation in C‑reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. J Rheumatol 2008;35(11):2171−8.
13. Юнонин И.Е., Бутусова С.В., Шилкина Н.П. Маркеры активации эндотелия при системной красной волчанке. Цитокины и воспаление 2011;(1):26−9.
14. Панафидина Т.А., Попкова Т.В., Алекберова З.С. и др. Значение факторов риска и С‑реактивного белка в развитии атеросклероза у женщин с системой красной волчанкой. Клиническая медицина 2006; 84(10):49−54.
15. Rezaieyazdi Z., Sahebari M., Hatef M.R., еt al. Is there any correlation between high sensitive
16. CRP and disease activity in systemic lupus erythematosus? Lupus 2011; 20(14):1494−500.
17. Amezcua‑Guerra L.M., Springall R., Arrieta‑Alvarado A.A., et al. C‑reactive protein and complement components but not other acute‑phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin Lab 2011;57(7−8):607−13.
18. Amezcua‑Guerra L.M., Márquez‑Velasco R., Bojalil R. Erosive arthritis in systemic lupus erythematosus is associated with high serumC‑reactive protein and anti‑cyclic citrullinated peptide antibodies. Inflamm Res 2008; 57(12):555−7.
19. Lozovoy M.A., Simão A.N., Hohmann M.S., et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus 2011; 20(13):1356−64.
20. Kim H.A., Chun H.Y., Kim S.H., et al. C‑reactive protein gene polymorphisms in disease susceptibility and clinical manifestations of Korean systemic lupus erythematosus. J Rheumatol 2009;36(10):2238−43.
21. Enocsson H., Sjöwall C., Skogh T., et al. Interferon‑alpha mediates suppression of C‑reactive protein: explanation for muted C‑reactive protein response in lupus flares? Arthritis Rheum 2009;60(12):3755−60.
22. Williams R.C., Harmon M.E., Burlingame R., Du Clos T.W. Studies of serum C‑reactive protein in systemic lupus erythematosus. Rheumatol 2005;32(3):454−61.
23. Plazak W., Pasowicz M., Kostkiewicz M., et al. Influence of chronic inflammation and autoimmunity
24. on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res 2011;60(10):973−80.
25. Plazak W., Gryga K., Milewski M., et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus 2011;20(9):936−44.
26. Kiani A.N., Post W.S., Magder L.S., Petri M. Predictors of progression in atherosclerosis over
27. years in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50(11):2071−9.
28. Albar Z., Wijaya L.K. Is there a relationship between serum C‑reactive protein level and dyslipidaemia in systemic lupus erythematosus? Acta Med Indones 2006;38(1):23−8.
29. Bis J.C., Eiriksdottir G., Lu C., еt al. Meta‑analysis of genome‑wide association studies in >80 000 subjects identifies multiple loci for C‑reactive protein levels. Circulation 2011;123(7):731−8.
30. Kaptoge S., Di Angelantonio E., Lowe G., et al. С‑reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta‑analysis. Lancet
31. ;375(9709):132−40.
32. Dhaun N., Lilitkarntakul P., Macintyre I.M., et al. Urinary endothelin‑1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 2009;296(6):1477−83.
33. Sjöwall C., Zickert A., Skogh T., et al. Serum levels of autoantibodies against C‑reactive protein
34. correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther
35. ;11(6):188.
36. Tan Y., Yu F., Yang H., et al. Autoantibodies against monomeric C‑reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial
37. lesions. Hum Immunol 2008;69(12):840−4.
38. Киселева А.Г., Орлова Г.М., Бердникова И.А., Фереферова Н.М. Хроническая болезнь почек как фактор риска атеросклероза у больных системной красной волчанкой. Сибирский медицинский журнал 2009;(1):92−4.
39. He C.S., Shi W., Ye Z.M., et al. Cardiovascular risk profile in systemic lupus erythematosus: a cross‑sectional study of 879 patients (in Chinese). Nan Fang Yi Ke Da Xue Xue Bao 2011;31(11):1910−3.
40. Wetterö J., Nilsson L., Jonasson L., Sjöwall C. Reduced serum levels of autoantibodies against monomeric C‑reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 2009;400(1−2):128−31.
41. Laiho K., Tiitinen S., Teppo AM., et al. Serum C‑reactive protein is rarely lost into urine in patients with secondary amyloidosis and proteinuria. Clin Rheumatol 1998;17(3):234−5.
Review
For citations:
Noskov S.M., Vasilevskaja O.A., Noskova T.S., Arzimanova N.A. THE SIGNIFICANCE OF C‑REACTIVE PROTEIN IN SYSTEMIC LUPUS ERYTHEMATOSUS. The Clinician. 2012;6(1):10-14. (In Russ.) https://doi.org/10.17650/1818-8338-2012-1-10-14
Views:
6345
Email this article 